anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemistry. ^ SUBSTANCE: invention refers to the field of disinfection and sterilisation. The bactericide compositions including dilutant and bactericide compound with formula whereat X is halogen as well as the ways of such compositions application for bacteria extermination, disinfection and sterilisation are revealed. The said compositions can include the bactericide compound in the amount enough for extermination of at least 1ù106 bacteria Mycobacterium terrae during less than 1 hour (according to the bacterial suspension test at 20C). ^ EFFECT: possibility of the disinfection and sterilisation with the compound having the dyeing properties weaker than phthalic aldehyde dyeing properties. ^ 14 cl, 17 tbl, 11 ex
The pathogenesis of Alzheimer disease (AD) involves complex gene regulatory changes across different cell types. To help decipher this complexity, we introduce single-cell Bayesian biclustering (scBC), a framework for identifying cell-specific gene network biomarkers in scRNA and snRNA-seq data. Through biclustering, scBC enables the analysis of perturbations in functional gene modules at the single-cell level. Applying the scBC framework to AD snRNA-seq data reveals the perturbations within gene modules across distinct cell groups and sheds light on gene-cell correlations during AD progression. Notably, our method helps to overcome common challenges in single-cell data analysis, including batch effects and dropout events. Incorporating prior knowledge further enables the framework to yield more biologically interpretable results. Comparative analyses on simulated and real-world datasets demonstrate the precision and robustness of our approach compared to other state-of-the-art biclustering methods. scBC holds potential for unraveling the mechanisms underlying polygenic diseases characterized by intricate gene coexpression patterns.
This trial was designed to be a randomized, single-center, double-blind, placebo-controlled trial. A total of 68 elderly patients from two ICUs will be randomly allocated at a 1:1 ratio to the intervention group or the control group. Both groups will receive the ABCDEF (A2F) bundle strategy recommended by guidelines, a multicomponent approach including pain and delirium management, breathing trial practice, analgesic and sedation usage control, family engagement and so on, to prevent delirium. The intervention group will additionally receive aromatherapy lasting for five days. The primary outcome is the prevalence of delirium. Secondary outcomes include the severity and duration of delirium, the length of ICU stay, the duration of physical restraint, the duration of analgesic and sedative medication and the 28-day mortality rate. We will use the CAM-ICU and CAM-S to measure the prevalence and severity of delirium, and analyses of variance (ANOVAs) or repeated-measures ANOVAs and Wilcoxon rank-sum tests to analyze the observation results.
The invention discloses an application of a Chinese patent drug to preparation of a medicament for restraining BGC-823 cell proliferation. The Chinese patent drug refers to Shuanghu liver clearing particles, which comprise Wuling bacterium powder serving as a major component, contain 19 kinds of amino acids such as adenosine, polysaccharides, sterol and glutamic acid, Y-aminobutyric acid, lysine and the like, further contain a plurality of components such as vitamins (VitE, B1, B6, K1 and the like), trace elements (Zn, Fe, Ca and the like) and the like. The Chinese patent drug has the effects of reinforcing the kidney and brain and nourishing the heart to calm the mind, and is suitable for heart-kidney imbalance of neurasthenia with manifestations of insomnia, amnesia, general lassitude, soreness and weakness of waist and knees, soft pulse or myasthenia gravis and the like. The Chinese patent drug is suggested to be taken orally three times every day, by three particles at one time, or is taken by following the doctor's advice. Every particle is o.33g by weight. According to tests, the Chinese patent drug can be used for restraining BGC-823 cell proliferation.
Participants with treatment-naïve melanoma will receive ASP1012 in a 21-day cycle. Pembrolizumab will also be administered every three weeks in a 21-day cycle, for up to 3 doses.
Pre-operative resolution of pulmonary hypertension would clearly provide the best long-term outcome for these patients, allowing a definitive surgical procedure. There are no reported cases of resolution of pulmonary hypertension with the use of pulmonary vasodilators allowing successful ASD closure.

We report the case of a patient with trisomy 21 and a primum atrial septum defect with associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days of life. Elevated pulmonary pressures were documented by cardiac catheterization during which the patient was found to have minimally responsive pulmonary vasculature to the administration of oxygen. He was started on pulmonary vasodilators which were continued for the following 5 months which resulted in gradual reduction in estimated PA pressure allowing successful closure of the primum ASD and repair of the cleft mitral valve. Following surgery, he was not restarted on pulmonary vasodilators and has continued to do well. The ability to reverse his pulmonary hypertension through the use of pulmonary vasodilators made him a candidate for his successful, definitive surgical repair. He currently has no residual cardiac problems and requires no cardiac medications. There will be no patient follow-up.
The participant will recite their trauma narrative to the psychologist for 10-20 minutes. However, during each recitation, a "mismatch" condition, different for each session, will be added to the reactivation procedure by having the participant do the following (in order of sessions.
BACKGROUND: Periplex® is a rapid point-of-care test based on the detection of interleukin-6 (IL-6) or matrix metalloproteinase-8 (MMP-8) to diagnose peritonitis in peritoneal dialysis (PD) patients.
METHODS: This single-centre study was conducted in Singapore General Hospital from 2019 to 2022. The study recruited PD patients suspected of having peritonitis. Periplex was performed at the presentation and recovery of peritonitis. Primary outcomes were sensitivity and specificity of Periplex at presentation. The positive and negative predictive values of tests were also performed.
RESULTS: A total of 120 patients were included in the study. The mean age was 60.9 ± 14.9 years, 53% were male, 79% were Chinese and 47.5% had diabetes mellitus. Periplex was positive in all patients with peritonitis (n = 114); sensitivity of 100%; 95% confidence interval (CI): 100-100%. Periplex was falsely positive in three patients with non-infective eosinophilic peritonitis, resulting in a low specificity of 50%; 95% CI: 41.1-59.0%. Periplex had a positive predictive value of 97.4% and a negative predictive value of 100%. During recovery from peritonitis, Periplex had high specificity (93.6%) and negative predictive value (98.7%) to indicate the resolution of infection. MMP-8 was more sensitive than IL-6 in detecting peritonitis. Periplex was positive in all patients with peritonitis regardless of the types of PD solutions used.
CONCLUSIONS: Periplex had high sensitivity, and positive and negative predictive values in the diagnosis of peritonitis can be considered as a screening tool for peritonitis. Given its high specificity and negative predictive value, it may also be used to document the resolution of peritonitis.
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) represents one of the most malignant cancers worldwide, with poor survival. Experimental evidence implies that glycolysis/hypoxia is associated with HNSCC. In this study, we aimed to construct a novel glycolysis-/hypoxia-related gene (GHRG) signature for survival prediction of HNSCC.
METHODS: A multistage screening strategy was used to establish the GHRG prognostic model by univariate/least absolute shrinkage and selection operator (LASSO)/step multivariate Cox regressions from The Cancer Genome Atlas cohort. A nomogram was constructed to quantify the survival probability. Correlations between risk score and immune infiltration and chemotherapy sensitivity were explored.
RESULTS: We established a 12-GHRG mRNA signature to predict the prognosis in HNSCC patients. Patients in the high-risk score group had a much worse prognosis. The predictive power of the model was validated by external HNSCC cohorts, and the model was identified as an independent factor for survival prediction. Immune infiltration analysis showed that the high-risk score group had an immunosuppressive microenvironment. Finally, the model was effective in predicting chemotherapeutic sensitivity.
CONCLUSIONS: Our study demonstrated that the GHRG model is a robust prognostic tool for survival prediction of HNSCC. Findings of this work provide novel insights for immune infiltration and chemotherapy of HNSCC, and may be applied clinically to guide therapeutic strategies.
Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
For all townships within the intervention arm, we have constructed a pay-for-population mechanism to incentivize all medical practitioners to care for population health within each township. For smokers, we will provide a multi-component intervention: (1) NicQuit, a CBT-based digital health intervention for those who use intelligent mobile phones; (2) community-based pulmonary function test; (3) health education and encouragement to seek medication in superior hospitals for those spirometry-defined COPD patients; (4) CBT-based health education to the abnormal BMI; (5) health education to smoking cessation; (6) Active recruitment of smokers with high blood pressure or high blood glucose measurement. Intensive follow-ups will be at month 3, 6, and 12.
The invention relates to the technical field of biomedicines and relates to a hypoxia responsive liposome preparation, and preparation and applications thereof. In particular, the invention relates to hypoxia responsive liposome-AQ4N-dihydroporphin e6 and preparation and application thereof, and especially, application thereof in enhancement of killing cells in tumor hypoxia zones in photodynamics therapy. The liposome preparation is composed of a liposome, AQ4N and dihydroporphin e6, has uniform particle size and is excellent in dispersion in water. The particle size of the liposome preparation is mainly about 100 nm in water. The liposome preparation can carry photosensitive molecules and dimethyldiguanide and is an ideal medicine carrier, and also has excellent in-vivo pharmacokinetics behavior. A test proves that the liposome-AQ4N-dihydroporphin e6 preparation is very-highly enriched at tumor parts, so that after the photodynamics therapy, the preparation can cause a more serious hypoxia status in the tumor zone, thereby improving the killing effect on the hypoxia cells of the AQ4N and obtaining excellent synergistic therapy effects on tumor.
The invention discloses a bacillus subtilis for producing complex enzyme, a culture method and application. A Bacillus subtilis Q3 producing complex enzyme is preserved in China center for type culture Collection in 2017 at 17.11.13.address eight-way Wuhan university No. 299 in Wuchang district, Wuhan city, Hubei province, with the strain preservation number of CCTCC NO: and M2017701. The bacillus subtilis disclosed by the invention is separated from leaf mold, can produce cellulase and pectinase, and has an inhibiting effect on common pathogenic bacteria. The Bacillus subtilis can be used as animal feed additive. The application of the Q3 bacteria for fermenting the echinacea purpurea can improve the release of effective components in the echinacea purpurea, improve the growth promotion, the immunity enhancement and the disease prevention and treatment effects of the echinacea purpurea. The bacterium and the echinacea fermentation preparation have good market application prospect.
The nanoparticles are obtained by desolvatation of the methyl vinyl ether copolymer and maleic anhydride with a hydroalcoholic phase of a solution in acetone. Subsequently, the particles obtained are treated with crosslinking agents (diamines or proteins) with the aim of extending their useful life and are then optionally incubated with a drug that will be transported to the surface. The nanoparticles may also contain the drug in encapsulated form, which would then be added during desolvatation. In the case of nanoparticle-ligand conjugates, the nanoparticles previously obtained and containing inside the drug to be transported are incubated with the ligand or molecule that will provide the property of specifically recognizing a given recipient of the organism. These pharmaceutical forms have the aim of providing improved transport of the drug or biologically active molecule to its site of action and/or absorption. This property improves the specificity and efficiency of said drugs.
The control group was given no intervention other than standard care (breathing exercise with Triflo, early ambulation, frequent position changes in bed) and treatment, which is the standard protocol of the Cardiovascular Surgery Service, by the clinic nurse and physician on the 1st, 2nd, 3rd and 4th days after surgery. Will not be implemented.
PURPOSE:To increase the yield of low-MW heparin by decreasing side reactions to thereby facilitate the control of the reaction, by reacting heparin with ozone in the presence or absence of a peroxide. CONSTITUTION:Heparin is reacted with ozone in the presence or absence of a peroxide. This reaction is carried out in such a way that a heparin solution is prepared and ozone is added to this solution to react with heparin. The heparin concentration of this solution is preferably 1-20wt%. It is preferable to add 0.5-20pts.wt. ozone per hr to 100pts.wt. heparin solution. Although said reaction may be carried out in a pH range as wide as about 1-10, it is preferable to carry out the reaction near neutrality (pH of 6-8) at which side reactions such as elimination of sulfate or acetyl groups difficultly occur. Although the reaction can proceed more easily when the temperature is higher, a temperature of about 40 deg.C is the most desirable because heparin is relatively unstable at high temperatures.
PURPOSE:To obtain the subject composition useful for cleaning clothes, skin, hair, etc., having excellent hard water resistance and dispersibility, highly preventing effect on recontamination, extremely low irritation to skin, containing an alpha-sulfo fatty acid derivative having a specific structure. CONSTITUTION:The objective composition comprises preferably 5-40wt.% of an alpha-sulfo fatty acid derivative of formula I (R1 and R2 are 6-18C alkyl or alkenyl; R3 is H, l-6C alkyl, etc.; M1 and M2 are H, alkali metal, etc.; Z is 2-6C straight-chain or branched chain alkylene or 3-8C alkylene containing hydroxyl group as substituent group) (e.g. Na salt of monoethanolamine bis alpha-sulfopalmitic acid amide ester) as a cleaning agent component. The compound of formula I, for example, is obtained by a method of treating a compound of formula II with thionyl chloride, amidating the prepared acid halide with an amino-alcohol of the formula HR3N(Z)OH, esterifying the prepared compound of formula III with an A-sulfo fatty acid of formula IV and optionally neutralizing.
Participants may be referred for screening at Medical College of Wisconsin (MCW) in two possible mechanisms: participant contact study staff from information on Clinical Trials Science Institute (CTSI) FACT website or referral from treating Hematologist or Oncologist. At MCW, an EPIC report will be generated to identify people with catheter related thrombosis (CRT). The treating provider would then be contacted to determine if referral to the study was appropriate. Subjects at Ohio State University (OSU) will be referred from the treating Hematologist or Oncologist. A report generated in Epic will be used to identify people with CRT. The treating provider would then be contacted to determine if referral to the study was appropriate. Participants will be given printed information about the study or verbal explanation using the informational flyer. Verbal consent will be obtained to be screened for participation and contacted by study personnel. Screening will be completed by BloodCenter of Wisconsin (BCW) nurse coordinator. We aim to consent and enroll patients after diagnosis of catheter-related thrombosis and prior to catheter removal. Consent and enrollment (Visit 1) must occur prior to discontinuation of anticoagulation. Participants will be treated with either enoxaparin for one month following catheter removal, or direct oral anticoagulant treatment (apixaban, rivaroxaban, dabigatran, or edoxaban). Anticoagulation will be continued for 1 month after catheter removal. The minimum duration of anticoagulation will be one month and maximum duration is 7 months. The cost of enoxaparin will be the responsibility of the participant as use of the medication is part of routine care. Subjects will be contacted by telephone prior to discontinuation of anticoagulation to review study protocol, assess for bleeding, and see if any continuation rules apply and arrange for research visit 2 in the following 1-2 weeks. Visits 3 and 4 will occur 3 and 6 months after catheter removal, respectively. At visits 3 \& 4, Medical history, cancer history, and medications will be updated. At each visit, participants will be assessed for post-thrombotic syndrome using the modified Villalta scale and functional limitation using the DASH questionnaire. At MCW, surveys will be administered by the research coordinator and/or Translational Research Unit (TRU) staff and physical examination will be completed by BCW nurse coordinator. At OSU, surveys will be administered by research coordinators and physical examination will be administered by research nurse coordinator. Laboratory samples will be obtained for MCW participants only.
People with substance use disorders (SUD) have a high prevalence of chronic hepatitis C virus (HCV) infection and mental health disorders. We aimed to assess the impact of integrated HCV treatment on psychological distress measured by Hopkins-symptom-checklist-10 (SCL-10). This multi-center randomized controlled trial evaluated psychological distress as a secondary outcome of integrated HCV treatment (INTRO-HCV trial). From 2017 to 2019, 289 participants were randomly assigned to receive either integrated or standard HCV treatment with direct-acting antiviral therapy. Integrated HCV treatment was delivered in eight decentralized outpatient opioid agonist therapy clinics and two community care centers; standard treatment was delivered in internal medicine outpatient clinics at centralized hospitals. Participants in the integrated treatment arm had a sustained virologic response of 93% compared to 73% for those in standard treatment arm. Psychological distress was assessed using SCL-10 prior to initiation of HCV treatment and 12 weeks after treatment completion. The mean SCL-10 score prior to HCV treatment was 2.2 (standard deviation [SD]: 0.7) for patients receiving integrated HCV treatment and 2.2 (SD: 0.8) for those receiving standard HCV treatment. Twelve weeks after the end of treatment, the mean SCL-10 score change was - 0.1 (- 0.3;0.0) in the integrated compared to the standard arm. Psychological distress did not substantially change during the treatment period and was not significantly different between the treatment arms.
Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
This is a randomized, double-blind, placebo-controlled Phase 1/2 study of the safety and immunogenicity of AVX502 vaccine at two dosage levels and two routes of administration in healthy volunteers conducted at a single research center. A total of 216 participants will be enrolled. Participants will be randomized to receive active vaccine at one of two dosage levels or placebo in a 4:4:1 ratio. Within each active dosage level or placebo subgroup, participants will be randomized to receive their injections by either IM or SC injection in a 1:1 ratio, and will also be randomized to receive either 1 injection (at Week 0) or 2 injections (1 at each of two visits at Weeks 0 and 8) in a 1:1 ratio. Vaccine will be administered by a study nurse in an outpatient setting and all participants will be followed for 4 months after the first immunization. Safety data will include local and systemic reactogenicity after each dose of vaccine, collected in a systematic format using a subject memory aid and a standard grading scale, specific safety laboratory parameters and general AEs. Immunogenicity data will be obtained by collecting blood at defined time points before and after immunization and separating serum (for measurement of antibodies to HA by ELISA and hemagglutination inhibition assays and to the vaccine vector by a VRP neutralization assay) and peripheral blood mononuclear cells (PMBC) (for measurement of cellular immune responses to HA peptides).
Megace® ES oral suspension contains megestrol acetate, a synthetic derivative of the naturally occurring steroid hormone, progesterone. Megestrol acetate is a white, crystalline solid chemically designated as 17-Hydroxy-6-methyl pregna-4,6-diene-3,20-dione acetate. Solubility at 37° C in water is 2 mcg per mL, solubility in plasma is 24 mcg per mL. Its molecular weight is 384.52.

The chemical formula is C 24H32O4 and the structural formula is represented as follows:

Megace® ES is an oral suspension containing 125 mg of megestrol acetate per mL.

Megace® ES oral suspension contains the following inactive ingredients: alcohol (max 0.06% v/v from flavor), artificial lime flavor, citric acid monohydrate, docusate sodium, hydroxypropyl methylcellulose (hypromellose), natural and artificial lemon flavor, purified water, sodium benzoate, sodium citrate dihydrate, and sucrose.